About Bernard Lyons
Form D filings for Vitara Biomedical from 2022 to 2024 list Bernard Lyons as interim chief executive officer and director.
Bernard Lyons first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Bernard Lyons in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Bernard Lyons works with at each company, as listed on that company's latest Form D.
Vitara Biomedical, Inc. · Form D, Oct 28, 2024
TT
Thomas Todorow
Director
IR
Ian Ratcliffe
Director
MK
Manish Kothari
Director
DN
Diem Nguyen
Director
TF
Ted Fjallman
Director